{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:03:38Z","timestamp":1752667418461},"reference-count":17,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The management of acquired hypertrichosis (HT) is based on the search of the causes and subsequent specific treatment. However, simultaneous hair removal is important. No single method for hair removal is appropriate for all patients and skin areas. Treatment options are actually limited and clinical results are often unsatisfactory. Ornithine decarboxylase 1 (ODC1), an enzyme present in hair follicles, is considered as a potential target to inhibit hair growth. Only eflornithine hydrochloride, an inhibitor of ODC1, showed to be partially effective in the management of acquired HT.<\/jats:p><\/jats:sec>Aims<\/jats:title>The aim of our study was to evaluate the potential inhibition of ODC1 activity by a cream containing 4% capryloyl glycine, an ODC1 inhibitor, and 1% glycine soy\u2010fermented extract (soy isoflavonoids). Furthermore, we present the results of a placebo\u2010controlled clinical study that evaluated the efficacy and tolerability of this cream.<\/jats:p><\/jats:sec>Methods<\/jats:title>The ODC1 activity was detected by measuring absorbance at 340\u00a0nm. In the presence of ODC1 inhibitors, absorbance decreases as a function of inhibition. Difluoromethylornithine (DFMO) was provided as an inhibitor control. ODC1 activity inhibition was expressed as percentage of control (untreated sample). All data were presented as mean\u00a0\u00b1\u00a0standard deviation of three independent experiments. To determine if statistically significant differences between treatments were present, a t<\/jats:italic> test analysis was performed. The differences between groups were considered significant at p<\/jats:italic>\u00a0<\u00a00.05. Twelve Caucasian female adult patients, with HT located on the forearms, were enrolled. The study cream (product A) was applied twice\/day for four months on the right forearm. A placebo cream (product B) was applied twice\/day for four months on the left forearm. Clinical efficacy was evaluated by means of macrophotography.<\/jats:p><\/jats:sec>Results<\/jats:title>The cream significantly inhibited ODC1 activity (35.1\u00a0\u00b1\u00a00.5% inhibition, equivalent to a 64.9\u00a0\u00b1\u00a00.5% ODC1 activity). DFMO completely abolished the enzymatic activity (100\u00a0\u00b1\u00a05% inhibition, equivalent to 0\u00a0\u00b1\u00a05% ODC1 activity). All patients were considered evaluable. In 11 out of 12 patients (91.7%), who were treated with product A, an improvement was observed. No improvement was observed in patients treated with product B. The global assessment showed good efficacy in 7 patients (58.3%) and moderate efficacy in 5 patients (41.7%) treated with the product A. No efficacy was detected in patients treated with product B.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The study cream showed to be effective in Caucasian, adult, female patients with hypertrichosis located on the forearms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.14096","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T05:46:31Z","timestamp":1619934391000},"page":"18-22","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Capryloyl glycine and soy isoflavonoids in hypertrichosis: An experimental and placebo\u2010controlled clinical study"],"prefix":"10.1111","volume":"20","author":[{"given":"Mauro","family":"Barbareschi","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Benetti","sequence":"additional","affiliation":[{"name":"European Center for the Sustainable Impact of Nanotechnology (ECSIN) ECAMRICERT SRL Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gaio","sequence":"additional","affiliation":[{"name":"European Center for the Sustainable Impact of Nanotechnology (ECSIN) ECAMRICERT SRL Padova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Angileri","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Veraldi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.100"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203090-00004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(99)80073-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/360355a0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079901750176735"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100603.x"},{"issue":"2","key":"e_1_2_8_8_1","first-page":"379","article-title":"A randomized, double\u2010blind, vehicle\u2010controlled study to evaluate the efficacy and safety of MAS063D in the treatment of mild to moderate atopic dermatitis","volume":"18","author":"Belloni G","year":"2004","journal-title":"JEADV"},{"key":"e_1_2_8_9_1","first-page":"31","article-title":"A randomised, double\u2010blind, vehicle\u2010controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis","volume":"15","author":"Belloni G","year":"2005","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_10_1","first-page":"AB84","article-title":"A multicenter randomized, vehicle\u2010controlled, double\u2010blind clinical study to examine the safety and efficacy of MAS063DP in the management of AD","volume":"54","author":"Abramovits W","year":"2006","journal-title":"JAAD"},{"key":"e_1_2_8_11_1","first-page":"236","article-title":"Adult Atopiclair Study Group. A multicenter, randomized, vehicle\u2010controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults","volume":"5","author":"Abramovits W","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.11.031"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802232799"},{"key":"e_1_2_8_14_1","first-page":"537","article-title":"Treatment of pruritus in mild\u2010to\u2010moderate atopic dermatitis with a topical non\u2010steroidal agent","volume":"8","author":"Veraldi S","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_15_1","first-page":"280","article-title":"Clinical inquiries. Do nonmedicated topicals relieve childhood eczema?","volume":"58","author":"Yates JE","year":"2009","journal-title":"J Fam Pract"},{"key":"e_1_2_8_16_1","first-page":"531","article-title":"An over\u2010the\u2010counter moisturizer is as clinically effective as, and more cost\u2010effective than, prescription barrier creams in the treatment of children with mild\u2010to\u2010moderate atopic dermatitis: a randomized, controlled trial","volume":"10","author":"Miller DW","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_17_1","first-page":"169","article-title":"Cost\u2010effectiveness study of pediatric atopic dermatitis in Asia: Atopiclair vs. regular emollient (AD\u2010ATOP)","volume":"14","author":"Tang MB","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13215"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.14096","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:23:31Z","timestamp":1692843811000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.14096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/jocd.14096"],"URL":"https:\/\/doi.org\/10.1111\/jocd.14096","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2021-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}